ozoralizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoclonal antibodies (humanized origin); lymphocyte	5723	1167985-17-2

Description:

Molecule	Description
Molfile Synonyms: ozoralizumab ozoralizumab (genetical recombination) nanozora ATN-103 PF-5230896	Ozoralizumab is a new type of antibody that can block the activity of TNFalpha, a protein that causes inflammation in the body. It is made of three small molecules called NANOBODIES; two of these NANOBODIES attach to TNFalpha and prevent it from binding to its receptors. The third NANOBODY binds to a protein in the blood called HSA, which helps ozoralizumab stay longer in the body. Ozoralizumab is smaller and more stable than conventional antibodies, and it may have fewer side effects. It is being developed as a treatment for rheumatoid arthritis and other inflammatory diseases. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

ozoralizumab
ozoralizumab (genetical recombination)
nanozora
ATN-103
PF-5230896

Ozoralizumab is a new type of antibody that can block the activity of TNFalpha, a protein that causes inflammation in the body. It is made of three small molecules called NANOBODIES; two of these NANOBODIES attach to TNFalpha and prevent it from binding to its receptors. The third NANOBODY binds to a protein in the blood called HSA, which helps ozoralizumab stay longer in the body. Ozoralizumab is smaller and more stable than conventional antibodies, and it may have fewer side effects. It is being developed as a treatment for rheumatoid arthritis and other inflammatory diseases.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 26, 2022	PMDA	TAISHO PHARMACEUTICAL CO., LTD.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tumor necrosis factor	Cytokine	P01375	TNFA_HUMAN	INHIBITOR	Kd	10.69		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
CHEMBL1743054	ChEMBL_ID
9638	IUPHAR_LIGAND_ID
DB12014	DRUGBANK_ID
C4519741	UMLSCUI
9369	INN_ID
D09944	KEGG_DRUG
05ZCK72TXZ	UNII

Pharmaceutical products:

None